Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2007 1
2008 1
2011 3
2012 1
2013 1
2014 3
2015 2
2016 4
2017 2
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
[Radiation therapy of sinonasal natural killer/T-cell lymphoma].
Riet FG, Canova CH, Gabarre J, Ben Hassine S, Kamsu Kom L, Mazeron JJ, Feuvret L. Riet FG, et al. Among authors: kamsu kom l. Cancer Radiother. 2014 Mar;18(2):147-53; quiz 161, 163. doi: 10.1016/j.canrad.2013.11.009. Epub 2014 Jan 22. Cancer Radiother. 2014. PMID: 24462054 Review. French.
Treatment of grade II-III intracranial meningioma with helical tomotherapy.
Boulle G, Bracci S, Hitchcock K, Jacob J, Clausse E, Halley A, Belghith B, Kamsu Kom L, Canova CH, Bielle F, Chevalier A, Peyre M, Mazeron JJ, Maingon P, Feuvret L. Boulle G, et al. Among authors: kamsu kom l. J Clin Neurosci. 2019 Jan;59:190-196. doi: 10.1016/j.jocn.2018.10.073. Epub 2018 Oct 24. J Clin Neurosci. 2019. PMID: 30528356
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Désaubry L, Robert C, Vagner S. Boussemart L, et al. Among authors: kamsu kom n. Nature. 2014 Sep 4;513(7516):105-9. doi: 10.1038/nature13572. Epub 2014 Jul 27. Nature. 2014. PMID: 25079330
Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization.
Boussemart L, Girault I, Malka-Mahieu H, Mateus C, Routier E, Rubington M, Kamsu-Kom N, Thomas M, Tomasic G, Agoussi S, Breckler M, Laporte M, Lacroix L, Eggermont AM, Cavalcanti A, Grange F, Adam J, Vagner S, Robert C. Boussemart L, et al. Among authors: kamsu kom n. Cancer Res. 2016 Mar 15;76(6):1476-84. doi: 10.1158/0008-5472.CAN-15-2900-T. Epub 2016 Jan 29. Cancer Res. 2016. PMID: 26825172
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents.
Azan A, Caspers PJ, Bakker Schut TC, Roy S, Boutros C, Mateus C, Routier E, Besse B, Planchard D, Seck A, Kamsu Kom N, Tomasic G, Koljenović S, Noordhoek Hegt V, Texier M, Lanoy E, Eggermont AM, Paci A, Robert C, Puppels GJ, Mir LM. Azan A, et al. Among authors: kamsu kom n. Cancer Res. 2017 Jan 15;77(2):557-565. doi: 10.1158/0008-5472.CAN-16-1733. Epub 2016 Nov 11. Cancer Res. 2017. PMID: 27836854 Clinical Trial.
Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3.
Buart S, Terry S, Noman MZ, Lanoy E, Boutros C, Fogel P, Dessen P, Meurice G, Gaston-Mathé Y, Vielh P, Roy S, Routier E, Marty V, Ferlicot S, Legrès L, Bouchtaoui ME, Kamsu-Kom N, Muret J, Deutsch E, Eggermont A, Soria JC, Robert C, Chouaib S. Buart S, et al. Among authors: kamsu kom n. Oncotarget. 2017 Oct 30;8(65):108786-108801. doi: 10.18632/oncotarget.22150. eCollection 2017 Dec 12. Oncotarget. 2017. PMID: 29312568 Free PMC article.
Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.
Dercle L, Ammari S, Champiat S, Massard C, Ferté C, Taihi L, Seban RD, Aspeslagh S, Mahjoubi L, Kamsu-Kom N, Robert C, Marabelle A, Schlumberger M, Soria JC, Postel-Vinay S. Dercle L, et al. Among authors: kamsu kom n. Eur J Cancer. 2016 Sep;65:33-42. doi: 10.1016/j.ejca.2016.05.031. Epub 2016 Jul 21. Eur J Cancer. 2016. PMID: 27451022 Clinical Trial.
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, Soria JC, Malka D, Sarasin A, Larcher M, André J, Kamsu-Kom N, Boussemart L, Lacroix L, Spatz A, Eggermont AM, Druillennec S, Vagner S, Eychène A, Dumaz N, Robert C. Arnault JP, et al. Among authors: kamsu kom n. Clin Cancer Res. 2012 Jan 1;18(1):263-72. doi: 10.1158/1078-0432.CCR-11-1344. Epub 2011 Nov 17. Clin Cancer Res. 2012. PMID: 22096025
18 results